Form 4: Versant Venture Capital Reduces Stake in LENZ Therapeutics Through Pre-Planned Stock Sale

Versant Venture Capital, a significant shareholder and director in LENZ Therapeutics, Inc., has sold 350,000 shares of common stock for $29 per share as part of a pre-arranged Rule 10b5-1 trading plan.

Summary

• Versant Venture Capital VI, L.P., along with related entities Versant Ventures VI GP, L.P., Versant Ventures VI GP-GP, LLC, Versant Vantage II, L.P., Versant Vantage II GP, L.P., Versant Vantage II GP-GP, LLC, Versant Venture Capital VII, L.P., Versant Ventures VII GP, L.P., and Versant Ventures VII GP-GP, LLC, collectively reported as 10% owners and directors of LENZ Therapeutics, Inc. (LENZ).
• On June 10, 2025, Versant Venture Capital VI, L.P. disposed of 350,000 shares of LENZ Therapeutics common stock.
• The shares were sold at a price of $29 per share, totaling $10,150,000.
• The transaction was conducted under a Rule 10b5-1 pre-arranged trading plan, indicating it was scheduled in advance.
• Following this transaction, Versant Venture Capital VII, L.P. indirectly holds 1,248,789 shares.
• Versant Venture Capital VI, L.P. directly holds 2,101,199 shares.
• Versant Vantage II, L.P. indirectly holds 842,162 shares.
• The total beneficial ownership by the Versant entities after the reported transaction is 4,192,150 shares.

Sentiment

Score: 4

Explanation: The sentiment is moderately negative due to a significant insider sale by a major investor. Although it's a pre-planned Rule 10b5-1 transaction, which mitigates some of the immediate negative implications, it still signifies a reduction in a key stakeholder's ownership.

Negatives

• A significant insider sale by a major venture capital investor and 10% owner could be perceived negatively by the market, potentially signaling reduced confidence or a strategic portfolio rebalancing.
• The sale of 350,000 shares represents a substantial reduction in the direct holdings of Versant Venture Capital VI, L.P.

Risks

• Potential negative market reaction to the insider sale, which could lead to downward pressure on LENZ Therapeutics' stock price.
• Investor perception of reduced long-term commitment from a key institutional investor and director.

Future Outlook

This Form 4 filing does not provide any forward-looking statements or guidance regarding LENZ Therapeutics' future performance or strategic direction. It solely reports a past insider transaction.

Industry Context

This specific insider transaction by a venture capital firm in a biotechnology company is a routine disclosure for public companies. While it reflects a portfolio management decision by Versant, it does not inherently provide broader industry trends or competitive insights beyond the specific company's stock activity.

Related Party Transactions

• The reported transaction involves the sale of common stock by Versant Venture Capital entities, which are 10% owners and have director representation on LENZ Therapeutics' board, making this a related party transaction.

Stakeholder Impact

• Shareholders may interpret the insider sale as a bearish signal, potentially leading to a decrease in investor confidence and a negative impact on the stock price.
• The transaction reflects a portfolio management decision by Versant Venture Capital, which could influence other institutional investors' perceptions of LENZ Therapeutics.

Key Dates

Recommendation

Keywords

LENZ Therapeutics, Versant Venture Capital, SEC Form 4, Insider Sale, Stock Transaction, Beneficial Ownership, Rule 10b5-1, Biotechnology, Pharmaceuticals